Literature DB >> 15249438

Efficacy of flow- vs impedance-guided autoadjustable continuous positive airway pressure: a randomized cross-over trial.

Dirk A Pevernagie1, Pascal M Proot, Katrien B Hertegonne, Marleen C Neyens, Kristien P Hoornaert, Romain A Pauwels.   

Abstract

STUDY
OBJECTIVES: Autoadjustable continuous positive airway pressure (CPAP) devices are increasingly used in the treatment of obstructive sleep apnea (OSA). Since different measurements of upper airway obstruction are applied, it is uncertain whether these devices are equally effective in controlling sleep-disordered breathing. Hypothesizing that differences in therapeutic efficacy were to come out, we compared the performance of the AutoSet device (ResMed; Sydney, Australia), which features autoadjustable positive airway pressure (APAP) guided by detection of flow limitation (APAPfl), with the SOMNOsmart device (Weinmann; Hamburg, Germany), which features APAP guided by the forced oscillation technique (APAPfot).
DESIGN: A double-blind, randomized, cross-over trial.
SETTING: The sleep disorders center and sleep laboratory of a university hospital. PATIENTS AND
INTERVENTIONS: An overnight CPAP autotitration procedure was performed in 30 patients with OSA. A split-night protocol allowed that each patient used both devices. MEASUREMENTS AND
RESULTS: Using polysomnography, sleep, indexes of sleep-disordered breathing, snoring, and CPAP levels were recorded. No significant differences were found in conventional sleep variables. While the apnea-hypopnea index (AHI) was lower with APAPfl (3.5 +/- 5.6/h) as compared to APAPfot (9.9 +/- 31.0/h), the difference was not statistically significant (mean +/- SD). The snoring index, however, was significantly lower with APAPfl (35.3 +/- 53.7/h vs 111.6 +/- 175.4/h, respectively; p = 0.01). The median and 95th percentile pressure levels rose from wakefulness to sleep in APAPfl, but decreased in APAPfot. Higher pressure variability was present in the latter method.
CONCLUSIONS: These findings suggest that the APAPfl is superior to APAPfot in the control of snoring. While a lower AHI was achieved with APAPfl, at the expense of a higher median pressure but less pressure variability, the difference with APAPfot was not statistically significant.

Entities:  

Mesh:

Year:  2004        PMID: 15249438     DOI: 10.1378/chest.126.1.25

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Positive pressure therapy: a perspective on evidence-based outcomes and methods of application.

Authors:  Mark H Sanders; Josep M Montserrat; Ramon Farré; Rachel J Givelber
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

2.  Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report.

Authors:  Timothy I Morgenthaler; R Nisha Aurora; Terry Brown; Rochelle Zak; Cathy Alessi; Brian Boehlecke; Andrew L Chesson; Leah Friedman; Vishesh Kapur; Rama Maganti; Judith Owens; Jeffrey Pancer; Todd J Swick
Journal:  Sleep       Date:  2008-01       Impact factor: 5.849

3.  Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea.

Authors:  Barry Kennedy; Toby J Lasserson; Dariusz R Wozniak; Ian Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-12-02

4.  Reliability of home CPAP titration with different automatic CPAP devices.

Authors:  Frédéric Sériès; Julie Plante; Yves Lacasse
Journal:  Respir Res       Date:  2008-07-24

5.  Obstructive sleep apnea - management update.

Authors:  Craig A Hukins
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

6.  Novel Approach to Simulate Sleep Apnea Patients for Evaluating Positive Pressure Therapy Devices.

Authors:  Valentina Isetta; Josep M Montserrat; Raquel Santano; Alison J Wimms; Dinesh Ramanan; Holger Woehrle; Daniel Navajas; Ramon Farré
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.